

World Journal of *Clinical Oncology*

World J Clin Oncol 2015 April 10; 6(2): 16-21



Editorial Board

2015-2018

The *World Journal of Clinical Oncology* Editorial Board consists of 293 members, representing a team of worldwide experts in oncology. They are from 41 countries, including Argentina (1), Australia (6), Austria (2), Belgium (1), Brazil (1), Bulgaria (1), Canada (6), China (42), Cuba (1), Denmark (4), France (4), Germany (11), Greece (1), Hungary (1), India (7), Iran (2), Ireland (1), Israel (1), Italy (33), Japan (25), Malaysia (3), Netherlands (8), Norway (3), Peru (1), Poland (1), Portugal (2), Qatar (1), Romania (1), Russia (1), Saudi Arabia (3), Singapore (2), South Korea (12), Spain (11), Sri Lanka (1), Sweden (2), Switzerland (1), Syria (1), Turkey (7), United Kingdom (3), United States (77), and Viet Nam (1).

PRESIDENT AND EDITOR-IN-CHIEF

Godefridus J Peters, *Amsterdam*

GUEST EDITORIAL BOARD MEMBERS

Wei-Fan Chiang, *Tainan*
Chien Chou, *Taipei*
Shuang-En Chuang, *Zhunan Township*
Wen-Liang Fang, *Taipei*
Chao-Cheng Huang, *Kaohsiung*
Huang-Kai Kao, *Taoyuan*
Chun-Yen Lin, *Kweishan*
Jun-Yang Liou, *Zhunan*
See-Tong Pang, *Taoyuan*
Neng-Yao Shih, *Tainan*
Che-Chun Su, *Changhua*
Hao-Wei Teng, *Taipei*
Kuo-Wang Tsai, *Kaohsiung*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Marina Simian, *Buenos Aires*



Australia

David Alexander Brown, *Sydney*
Belamy B Cheung, *Sydney*
Angela Hong, *Sydney*
Helen Kavnoudias, *Melbourne*
Kum Kum Khanna, *Brisbane*
Feng Pan, *Hobart*



Austria

Andreas Leithner, *Graz*

Okay Saydam, *Vienna*



Belgium

Gérald E Piérard, *Liège*



Brazil

Katia Ramos Moreira Leite, *Sao Paulo*



Bulgaria

Julian Ananiev, *Stara Zagora*



Canada

Slimane Belbraouet, *Moncton*
Francesco Crea, *Vancouver*
Sharlene Gill, *Vancouver*
Anil Kapoor, *Hamilton*
Saroj Niraula, *Winnipeg*
Siyaram Pandey, *Windsor*



China

Nian-Yong Chen, *Chengdu*
James CS Chim, *Hong Kong*
William Chi-shing Cho, *Hong Kong*
Yong-Song Guan, *Chengdu*
Yi Ji, *Chengdu*
Fu Li, *Tianjin*
Lin-Wei Li, *Zhengzhou*
Xin-Xiang Li, *Shanghai*
Liu Liu, *Hefei*
Yun-Ping Luo, *Beijing*

Mao-Bin Meng, *Tianjin*

Tzi Bun Ng, *Hong Kong*

Yang-Lin Pan, *Xian*

Xiu-Feng Pang, *Shanghai*

Shu-Kui Qin, *Nanjing*

Xiao-Juan Sun, *Shenzhen*

Jian Suo, *Changchun*

Xing-Huan Wang, *Wuhan*

Yun-Shan Yang, *Hangzhou*

Lei Yao, *Shanghai*

Pei-Wu Yu, *Chongqing*

Yin-Hua Yu, *Shanghai*

Guo Yu, *Yangzhou*

Ke Zen, *Nanjing*

Li-Duan Zheng, *Wuhan*

Zhao-Hua Zhong, *Harbin*

Hai-Meng Zhou, *Beijing*

Sen-Lin Zhu, *Guangzhou*

Hong-Qing Zhuang, *Tianjin*



Cuba

Elia Neninger, *Havana*



Denmark

Pavel Gromov, *Copenhagen*

Andreas Kjaer, *Copenhagen*

Cathy Mitchelmore, *Roskilde*

Henrik Toft Sorensen, *Aarhus*



France

Gilles Houvenaeghel, *Marseille*

Fabrice Lecuru, *Paris*

Clara Nahmias, *Villejuif*

Palma Rocchi, *Marseille*

**Germany**

Malgorzata Banys-Paluchowski, *Hamburg*
 Alexandr Bazhin, *Munich*
 Wolfgang M Brueckl, *Nuremberg*
 Klaus Felix, *Heidelberg*
 Jan G Hengstler, *Dortmund*
 Jorg Kleeff, *Munich*
 Michael Pinkawa, *Aachen*
 Daniel Reim, *Munich*
 Rajkumar Savai, *Bad Nauheim*
 Manfred Schmitt, *Munich*
 Jurgen Veeck, *Aachen*

**Greece**

Vasilis Androutsopoulos, *Heraklion*

**Hungary**

Zsuzsa Schaff, *Budapest*

**India**

Imran Ali, *New Delhi*
 Sudhir Chandna, *Delhi*
 Subhjit Dey, *Gurgaon*
 Sachin B Ingle, *Latur*
 Chanakya Nath Kundu, *Bhubaneswar*
 Syed Musthapa Meeran, *lucknow*
 Suprava Patel, *Raipur*

**Iran**

Mojgan Hosseini, *Tehran*
 Ali Kabir, *Tehran*

**Ireland**

Michael Joseph Kerin, *Galway*

**Israel**

Rina Rosin-Arbesfeld, *Tel Aviv*

**Italy**

Luca Arcaini, *Pavia*
 Luigi Bagella, *Sassari*
 Giovanni Blandino, *Rome*
 Guido Bocci, *Pisa*
 Guido Cavaletti, *Monza*
 Fulvio Chiacciera, *Milan*
 Anita De Rossi, *Padova*
 Giuseppe Di Lorenzo, *NapAPOLI*
 Nicola Fazio, *Milan*
 Giammaria Fiorentini, *Pesaro*
 Robert Fruscio, *Monza*
 Marilena Valeria Iorio, *Milan*
 Marco La Torre, *Rome*
 Matteo Landriscina, *Foggia*

Giuseppe Lombardi, *Padua*
 Monica Mangoni, *Florence*
 Michele N Minuto, *Genoa*
 Simone Mocellin, *Padova*
 Luca Mologni, *Monza*
 Massimo Nabissi, *Camerino*
 Silvio Naviglio, *Naples*
 Nicola Normanno, *Naples*
 Francesca Pentimalli, *Avellino*
 Roberto Petrioli, *Siena*
 Giuseppe Procopio, *Milan*
 Tiziana Rancati, *Milan*
 Gian-Luigi Russo, *Avellino*
 Bruna Scaggiante, *Trieste*
 Alessandro Sciarra, *Rome*
 Giuseppe Servillo, *Perugia*
 Gilbert Spizzo, *Merano*
 Roberta Venturella, *Catanzaro*
 Giovanni Vitale, *Cusano Milanino*

**Japan**

Ujjal K Bhawal, *Matsudo*
 Xing Cui, *Chiba*
 Takanori Goi, *Yoshida-gun*
 Shuichi Hironaka, *Chiba*
 Mikito Inokuchi, *Tokyo*
 Hideki Kawai, *Akita*
 Naoko Iwahashi Kondo, *Fukuoka*
 Hiroki Kuniyasu, *Kashihara*
 Shoji Nagao, *Akashi*
 Jun Nakamura, *Saga*
 Atsushi Nanashima, *Nagasaki*
 Takuma Nomiya, *Chiba*
 Kojun Okamoto, *Hidaka*
 Youngjin Park, *Sendai*
 Hidefumi Sasaki, *Tokyo*
 Hiroto Shobaguchi, *Fukuoka*
 Koichi Suzuki, *Saitama*
 Kazuki Takakura, *Tokyo*
 Yoshifumi Takei, *Nagoya*
 Toshihiko Torigoe, *Sapporo*
 Masahiko Watanabe, *Kanagawa*
 Hiroko Yamashita, *Sapporo*
 Shozo Yokoyama, *Wakayama*
 Kazuhiro Yoshida, *Gifu*
 Yoichiro Yoshida, *Fukuoka*

**Malaysia**

Batoul Sadat Haerian, *Kuala Lumpur*
 Chee-Onn Leong, *Kuala Lumpur*
 Shing Cheng Tan, *Kubang Kerian*

**Netherlands**

Vikram Rao Bollineni, *Groningen*
 Elisa Giovannetti, *Amsterdam*
 Lukas Hawinkels, *Leiden*
 Martijn Ruben Meijerink, *Amsterdam*
 Godefridus J Peters, *Amsterdam*
 Judith Evelyn Raber-Durlacher, *Amsterdam*
 Pieter Christiaan van der Sluis, *Utrecht*
 Astrid AM van der Veldt, *Amsterdam*

**Norway**

Ingfrid S Haldorsen, *Bergen*

Line Merethe Oldervoll, *Trondheim*
 Shanbeh Zienolddiny, *Oslo*

**Peru**

Carlos A Castaneda, *Lima*

**Poland**

Antoni Mariusz Szczepanik, *Cracow*

**Portugal**

Antonio MF Araujo, *Porto*
 Ana Cristina Ramalinho, *Covilha*

**Qatar**

Julie VCM Decock, *Doha*

**Romania**

Valeriu Marin Surlin, *Craiova*

**Russia**

Alex Lyakhovich, *Novosibirsk*

**Saudi Arabia**

Mostafa Ahmed Arafa, *Riyadh*
 Ziyad Binkhathlan, *Riyadh*
 Mazen Hassanain, *Riyadh*

**Singapore**

Eddie Yin Kwee Ng, *Singapore*
 Veronique Kiak Mien Tan, *Singapore*

**South Korea**

Cheol-Hee Choi, *Gwangju*
 Ik-Soon Jang, *Daejeon*
 Chaeyong Jung, *Gwangju*
 Jong Duk Kim, *Daejeon*
 Gwang Ha Kim, *Busan*
 Eun Ju Kim, *Seoul*
 Lee Su Kim, *Anyang*
 Hee Sung Kim, *Seoul*
 Kwang dong Kim, *Jinju*
 Sang Moo Lim, *Seoul*
 Seong Woo Yoon, *Seoul*
 Dae Young Zang, *Anyang-si*

**Spain**

Emiliano Calvo, *Madrid*
 Manuel Fuentes, *Salamanca*
 Enrique Grande, *Madrid*
 Matilde Esther Leonart, *Barcelona*

José Antonio Lopez-Guerrero, *Valencia*
Gracia Merino, *Leon*
Jordi Muntane, *Seville*
Ernest Nadal, *L'Hospitalet*
Amalia Palacios-Eito, *Cordoba*
Isabel T Rubio, *Barcelona*
Albert Selva-O'Callaghan, *Barcelona*



Sri Lanka

Kemal I Deen, *Dehiwela*



Sweden

Yihai Cao, *Stockholm*
Hong Xie, *Stockholm*



Switzerland

Nicolas C Buchs, *Geneva*



Syria

Roger von Moos, *Chur*



Turkey

Ahmet Altun, *Sivas*
Beste Atasoy, *Istanbul*
Ahmet Dirier, *Gaziantep*
Ozkan Kanat, *Bursa*
Serhan Kupeli, *Adana*
Kazim Sahin, *Elazig*
Isik G Yulug, *Ankara*



United Kingdom

Andrew Gaya, *London*

Konstantinos Lasithiotakis, *York*
Sebastian Oltean, *Bristol*



United States

ARM Ruhul Amin, *Atlanta*
Soley Bayraktar, *Ardmore*
Amer Beitinjaneh, *Charlottesville*
Maurizio Bocchetta, *Maywood*
Deliang Cao, *Springfield*
Daniel VT Catenacci, *Chicago*
Zhe-Sheng Chen, *Queens*
Guan Chen, *Milwaukee*
Duc Phuc Do, *Chicago*
Cathy Eng, *Houston*
Jeffrey M Farma, *Philadelphia*
Markus H Frank, *Boston*
Sidney Wang Fu, *Washington*
Mei R Fu, *New York*
Siqing Fu, *Houston*
Song Gao, *Houston*
Mamdooh Ghoneum, *Los Angeles*
Ruben Rene Gonzalez-Perez, *Atlanta*
Rachel Nicole Grisham, *New York*
Sanjay Gupta, *Cleveland*
Gerald M Higa, *Morgantown*
Chung-Tsen Hsueh, *Loma Linda*
GK Jayaprakasha, *College Station*
Johnny Kao, *West Islip*
Nimmi Singh Kapoor, *Orange*
Arianna L Kim, *New York*
Mark Alan Klein, *Minneapolis*
Sunil Krishnan, *Houston*
Melanie Haas Kucherlapati, *Boston*
Mahmoud N Kulaylat, *Buffalo*
Adeyinka O Laiyemo, *Washington*
Marie Catherine Lee, *Tampa*
James W Lillard, *Atlanta*
Shiaw-Yih Lin, *Houston*
Wei Liu, *Frederick*
Zhao-Jun Liu, *Miami*
Jirong Long, *Nashville*
Jianrong Lu, *Gainesville*

James L Mulshine, *Chicago*
Ronald B Natale, *Los Angeles*
Matthew E Nielsen, *Chapel Hill*
Kutluk Oktay, *Valhalla*
Chung S Park, *Fargo*
Tayebeh Pourmotabbed, *Memphis*
Raj Pruthi, *Chapel Hill*
Jay Dilip Raman, *Hershey*
Jianyu Rao, *Los Angeles*
Gaiane M Rauch, *Houston*
William C Reinhold, *Bethesda*
Monica Rizzo, *Atlanta*
Eben L Rosenthal, *Birmingham*
Joan J Ryoo, *Los Angeles*
Virgilio S Sacchini, *New York*
Neeraj K Saxena, *Baltimore*
Caner Saygin, *Cleveland*
Masood A Shammas, *Boston*
Amar B Singh, *Omaha*
Khalid Sossey-Alaoui, *Cleveland*
Lu-Zhe Sun, *San Antonio*
Weijing Sun, *Pittsburgh*
Viqar Syed, *Bethesda*
Li Tao, *Fremont*
Anish Thomas, *Bethesda*
Reid Thompson, *Philadelphia*
Shahid Umar, *Kansas City*
Huan N Vu, *Richmond*
Chong-Zhi Wang, *Chicago*
Bin Wang, *Chester*
Jin Wang, *Houston*
Guojun Wu, *Detroit*
Michiko Yamagata, *Waltham*
Wannian Yang, *Danville*
Eddy S Yang, *Birmingham*
Jennifer Yunyan Zhang, *Durham*
Bin Zhang, *New York*
Shaying Zhao, *Athens*
Jin-Rong Zhou, *Boston*



Viet Nam

Phuc Van Pham, *Ho Chi Minh*



CASE REPORT

- 16 Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review
Cripe J, Eskander R, Tewari K

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Oncology*, Malgorzata Banyś-Paluchowski, MD, Chief Doctor, Senior Research Fellow, Senior Consultant/Research Fellow, Breast Cancer Center, Marienkrankenhaus Hamburg, Hamburg 20146, Germany

AIM AND SCOPE

World Journal of Clinical Oncology (World J Clin Oncol, WJCO), online ISSN 2218-4333, DOI: 10.5306 is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJCO covers a variety of clinical medical topics, including etiology, epidemiology, evidence-based medicine, informatics, diagnostic imaging, endoscopy, tumor recurrence and metastasis, tumor stem cells, radiotherapy, chemotherapy, interventional radiology, palliative therapy, clinical chemotherapy, biological therapy, minimally invasive therapy, physiotherapy, psycho-oncology, comprehensive therapy, and oncology-related nursing. Priority publication will be given to articles concerning diagnosis and treatment of oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJCO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Clinical Oncology is now indexed in PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Yue-Li Tian*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL
World Journal of Clinical Oncology

ISSN
ISSN 2218-4333 (online)

LAUNCH DATE
November 10, 2010

FREQUENCY
Bimonthly

EDITOR-IN-CHIEF
Godefridus J Peters, PhD, Professor, Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam 1081 HV, Netherlands

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Clinical Oncology
Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-59080039
Fax: +86-10-85381893
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLICATION DATE
April 10, 2015

COPYRIGHT
© 2015 Baishideng Publishing Group Inc. Articles

published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2218-4333/g_info_20100722172206.htm

ONLINE SUBMISSION
<http://www.wjgnet.com/esps/>

Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review

James Cripe, Ramez Eskander, Krishnansu Tewari

James Cripe, Ramez Eskander, Krishnansu Tewari, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, the University of California, Irvine Medical Center, Orange, CA 92701, United States

Author contributions: Cripe J, Eskander R and Tewari K contributed equally to this work; Cripe J drafted the manuscript; Eskander R made significant edits of intellectual content; Tewari K approved the overall works.

Ethics approval: The case report was approved by the University of California - Irvine.

Informed consent: The patient provided informed written consent prior to case review.

Conflict-of-interest: The authors have no financial or non-financial disclosures to make.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: James Cripe, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, the University of California, Irvine Medical Center, 101 the City Drive, Orange, CA 92701, United States. jjcripe@gmail.com

Telephone: +1-714-4566707

Received: December 24, 2014

Peer-review started: December 26, 2014

First decision: January 8, 2015

Revised: January 29, 2015

Accepted: February 10, 2015

Article in press: February 12, 2015

Published online: April 10, 2015

Abstract

Ectopic breast tissue is rare and typically presents as an axillary mass. Previous reports have identified ectopic breast tissue in the vulva, but malignancy is exceedingly uncommon. We present a 62 years old with

locally advanced breast carcinoma arising in the vulva demonstrates the utilization of sentinel lymph node mapping to identify metastatic lymph nodes previously unable to be identified *via* traditional surgical exploration. Our case supports the principles of adjuvant therapy for breast cancer to be applied to ectopic breast cancer arising in the vulva. A literature review highlights common key points in similar cases to guide management.

Key words: Vulvar cancer; Ectopic breast; Sentinel lymph node; Breast cancer; Vulvar breast cancer

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Our findings describe the presentation of ectopic breast cancer in the vulva. We demonstrate use of sentinel lymph node technology with identification of the sentinel node, only possible after the use of this technology. We conclude with a review of the literature outlining treatment of this enigmatic disease.

Cripe J, Eskander R, Tewari K. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. *World J Clin Oncol* 2015; 6(2): 16-21 Available from: URL: <http://www.wjgnet.com/2218-4333/full/v6/i2/16.htm> DOI: <http://dx.doi.org/10.5306/wjco.v6.i2.16>

INTRODUCTION

Ectopic breast tissue has been previously reported in various locations along the primitive milk line, from the axilla to the vulva (Figure 1). Axillary ectopic breast tissue is the most frequent location and the vulva being the least common site^[1]. Malignant ectopic breast tissue is rare, typically presenting as an axillary mass, with vulvar breast malignancy being exceedingly rare^[1]. In 1935, Green *et al*^[2] published the first case report




Figure 1 Ectopic breast tissue has been previously reported in various locations along the primitive milk line, from the axilla to the vulva.

of adenocarcinoma arising from breast tissue in the vulva. Although 22 cases of malignant vulvar breast tissue have been reported since then, there are no clear guidelines regarding surgical or adjuvant treatment. We present a case that outlines the diagnosis and management of primary breast cancer of the vulva, highlighting diagnostic dilemmas, the utility of sentinel node mapping and reinforcing the importance of a multidisciplinary approach in the management of this rare clinical entity.

CASE REPORT

A 62 years old Hispanic multiparous women noted a new 1.3 cm left labial mass for approximately 1 year and presented to her primary gynecologist for evaluation. She underwent a wide local excision that was noteworthy for an invasive ductal carcinoma arising in ectopic breast tissue. Final pathology was confirmed by independent review at two separate institutions. Immunohistochemical staining showed the lesion to be 95% estrogen receptor (ER) positive, 10% progesterone receptor (PR) positive, and human epidermal growth factor 2 (HER2) negative (Figure 2).

The patient underwent a magnetic resonance imaging of the breast that was negative for a breast primary malignancy. Approximately 1 mo after initial presentation in September of 2012, the patient was referred to gynecologic oncology and underwent a partial radical vulvectomy at the prior vulvar scar site. Final pathology was negative for residual disease and the patient, given absence of metastatic disease declined adjuvant therapy. The patient initiated close surveillance and had a Fluoro-deoxyglucose (FDG) Positron emission tomography (PET) scan in January 2013 with findings of suspicious left inguinal-femoral lymphadenopathy, with standard uptake value (SUV) of 8.1.

The patient was counseled to undergo left inguinal-femoral lymphadenectomy (LND). The dissection was completed superficial to the cribiform fascia and final pathology identified 14 lymph nodes ranging from 1.2-2.5 cm that were all negative for tumor. On follow up examination in April 2013, the patient was found to have a 1-2 mm firm, non-tender nodule under her healing scar. In office biopsy confirmed recurrent invasive ductal carcinoma, with identical histology to the previous primary lesion. A repeat wide local excision was performed in June 2013. Pathology from that surgical resection was negative for tumor.

A PET-CT in August 2013 was repeated and was significant for suspicious left inguinal lymph node measuring 1.1 cm × 1.6 cm with SUV of 8.2 (Figure 3). The patient returned to the operating room with preoperative technetium 99 lymphoscintigraphy and lymphazurin blue (injected into the previous left surgical site) lymph node localization (Figure 4). An inguinal incision was created and the Geiger counter was used to identify "hot" areas. Dissection continued until area of maximum radioactivity was encountered. A hot, blue, slightly firm, 1.2 cm left sentinel was identified superficial to the cribiform fascia and excised. Intraoperative frozen section was positive for metastasis and comprehensive LND was performed. Two additional left sentinels (both hot and blue) were positive for ductal carcinoma. A right-sided sentinel node was not identified, but given contralateral positive nodes a comprehensive right LND was performed. Final pathology (Figure 2) confirmed three positive sentinels and 14 negative left and right inguinofemoral nodes.

Metastatic workup was negative and the patient underwent intensity modulated radiation therapy (4500 cGy) with 5900 cGy boosts to the left groin. Chemotherapy included weekly taxol followed by adriamycin and cyclophosphamide. Following adjuvant therapy she started maintenance therapy with an aromatase inhibitor.

She is currently without evidence of disease recurrence 13 mo after sentinel lymph node detection.

DISCUSSION

Ectopic breast tissue is rare and accounts for 0.2%-0.6% of all breast cancers. Only 4% of these ectopic breast cancers are located in the vulva, making vulvar breast cancer exceedingly rare^[3]. Ectopic breast tissue originates in the fetus at the ectodermal mammary streak extending from the axilla to the groin as demonstrated in Figure 1. Most of this structure disappears with small portions persisting in the thorax. This primordial ectoderm penetrates the underlying mesenchyme and gives rise to small solid out buddings that canalize and form the lactiferous ducts and alveoli of the mammary gland^[4,5].

There have been 22 reported cases since Greene's index case report in 1935. The majority of these patients




Figure 2 Estrogen receptor staining of primary tumor (A), Her2neu staining of primary tumor (B), metastasis to the lymph node (C), progesterone receptor staining of primary tumor (D).



Figure 3 Patient returned to the operating room with preoperative technetium 99 lymphoscintigraphy and lymphazurin blue (injected into the previous left surgical site) lymph node localization.




Figure 4 Ectopic breast tissue originates in the fetus at the ectodermal mammary streak extending from the axilla to the groin. RT: Radiation therapy.

presented with an innocuous solitary lesion of the vulva (Table 1); upon surgical excision, adenocarcinoma or ductal carcinoma arising in normal appearing breast tissue was identified. Extensive preoperative imaging is traditionally used to exclude metastasis of a primary breast malignancy. Two of these reported cases were indeed metastatic from a primary breast lesion^[6,7]. Adjuvant chemotherapy and radiation treatment protocols are heterogeneous (Table 2) given the rare frequency of these lesions, and absence of standardized treatment paradigms. Anti-hormonal therapy has been used in 14 (13 Tamoxifen and 1 Aromatase) patients with ER/PR positive specimens with various outcomes. The use of trastuzumab in

HER2 positive cases has not been previously reported. The presence of metastatic tumor in regional lymph nodes remains the most significant prognostic factor for several malignancies, including breast cancer. Sixteen patients underwent inguinal LND with all 16 patients having lymph node involvement. Survival and adjuvant therapy data are outlined in Table 2. Sentinel lymph node mapping is a technique that minimizes morbidity while maintaining diagnostic accuracy by isolating the first or "sentinel" node to drain the affected area burdened with tumor. This is traditionally performed with injection of the tumor with isosulfan blue and a radiolabeled colloid, most often technetium 99. This technique was pioneered by Morton in the treatment

Table 1 Clinical presentations of vulvar-breast cancer

Ref.	Year	Age (yr)	Location	Size (cm)	Symptoms and duration	Duration (mo)
Greene ^[2]	1935	59	Right labia majora	20 × 15	Mass	12
Hendrix <i>et al</i> ^[14]	1956	58	Right Labia minora	3	Ulcerated mass	84
Guerry <i>et al</i> ^[6]	1976	62	Right labia minora	1.5	Mass	4
Guercio <i>et al</i> ^[15]	1984	49	Left labia majora	2	Mass	Unk
Cho <i>et al</i> ^[16]	1985	70	Right labia majora	3 × 4	Mass	30
Simon <i>et al</i> ^[17]	1988	60	Right labia majora	2 × 2	Ulcerated mass	36
Rose <i>et al</i> ^[18]	1990	68	Right labia majora	3.5 × 3.5	Mass	36
Di Bonito <i>et al</i> ^[19]	1992	46	Right labia majora	1.5	Ulcerated mass	24
Bailey <i>et al</i> ^[20]	1993	65	Right labia majora	3 × 2	Ulcerated mass	36
Levin <i>et al</i> ^[21]	1994	62	Left clitoris	2.5	Mass	Unk
Kennedy <i>et al</i> ^[7]	1997	71	Left labia majora	5	Ulceration and dysuria	1
Irvin <i>et al</i> ^[4]	1998	64	Left lateral mons	3	Indurated mass	48
Gorisek <i>et al</i> ^[22]	2000	81	Left labia majora	2 × 3	Ulcerated mass	Unk
Piura <i>et al</i> ^[23]	2002	69	Left labia majora	3	Ulcerated mas	Unk
Chung-Park <i>et al</i> ^[24]	2002	47	Right labia minora	2	Ulcerated mass	12
Yin <i>et al</i> ^[25]	2003	84	Mons	5	Swelling	24
Lopes <i>et al</i> ^[26]	2006	44	Left vulva	2	Mass	48
Fracchioli <i>et al</i> ^[27]	2006	57	Left vulva	1	Mass	Unk
North <i>et al</i> ^[28]	2006	49	Right labia minora and clitoris	1.5	Pain and pressure	Unk
			Left groin	2		
Naseer <i>et al</i> ^[29]	2011	57	Right labia majora	1.5	Non painful lesion	Unk
McMaster ^[30]	2013	60	Left labia majora	3	Pedunculated ulcerated mass	6
Bogani <i>et al</i> ^[13]	2013	71	Left labia Majora	4	Painful ulcerated mass	Unk
			Left groin	3		

Unk: Unknown.

of melanoma in the early 1990's^[8]. The assessment of regional lymph nodes in breast cancer paralleled the work in melanoma, in an effort to limit the morbidity of axillary lymph node dissection^[9]. Numerous clinical trials have detailed the effectiveness and reduced morbidity associated with sentinel lymph node dissection in breast cancer patients in both the primary surgical setting and following neoadjuvant therapy. Current American Society of Clinical Oncology (ASCO) guidelines recommends sentinel lymph node mapping as standard of care in breast cancer^[10].

Sentinel node mapping in vulvar cancer is a more contemporary topic with evolving literature, and has paralleled some advances in penile carcinoma lymphatic mapping. GROINS-V, an observational study, followed 403 patients with primary vulvar tumors less than 4 cm treated with sentinel node mapping. Eight patients had groin recurrence with a false negative rate of 5.9% and a false negative predictive value of 2.9%^[11]. Similar results were replicated in GOG protocol 173^[12], a phase 3 multi-institutional study of intraoperative lymphatic mapping in patients with invasive squamous cell carcinoma of the vulva. Inclusion criteria included depth of invasion > 1 mm and primary tumor size 2-6 cm. Four hundred and fifty-two patients underwent sentinel node mapping with 418 patients having a sentinel node identified. Eleven (8.3%) patients with negative sentinel lymph nodes had groin recurrence. The false negative rate in primary lesions < 4 cm was 2%, but with lesions > 4 cm the false negative rate was 4%^[11]. It is important to note that all patients in GOG protocol 173 underwent comprehensive LND after sentinel LND

regardless of its status. GROINS-V also identified a statistically significant decrease in wound breakdown, cellulitis, and lymphedema in patients undergoing sentinel lymph node mapping. Both studies provide evidence to support the incorporation of sentinel LND in the management of vulvar malignancies.

Our case utilized sentinel lymph node mapping at time of recurrence and precisely aided in the identification of the metastatic lymph nodes. This technology was not utilized in the primary surgical management due to uncertainties on how it would perform when the primary lesion was comprised of ectopic breast tissue. However, after failing to identify the PET positive nodes with standard LND, SLD was employed to identify and excise the lymph nodes.

Primary breast cancer originating in the vulva is rare and management strategies stem from individual case reports or case series. Current literature supports the use of sentinel lymph node mapping in vulvar cancer and we anticipate that future cases will utilize this practice. Bogani *et al*^[13] as well as our case have been the only published literature to utilize sentinel lymph node mapping after a previous LND. Both cases identified positive sentinel lymph nodes that were previously unable to have been resected. These findings may support the up-front use of sentinel lymph node localization.

From our review of the literature there are several key concepts in managing this rare malignancy. First, exclusion of a primary breast malignancy needs to be confirmed by pretreatment imaging and physical examination. Next, occurrence of positive nodes is

Table 2 Previously published reports

Ref.	Treatment	Histology	ER	PR	Her2-neu	LN	Status	Follow up (mo)
Greene ^[2]	None	AC + S	NA	NA	NA	NA	DOD	1
Hendrix <i>et al</i> ^[14]	Surgery	AC	NA	NA	NA	NA	DOD	4
Guerry <i>et al</i> ^[6]	Surgery	DC	NA	NA	NA	NA	DOD	24
Guercio <i>et al</i> ^[15]	Surgery + RT	LO	NA	NA	NA	11/24	NED	36
Cho <i>et al</i> ^[16]	Surgery + tamoxifen	AC	+	+	NA	2/9	NED	24
Simon <i>et al</i> ^[17]	Surgery + tamoxifen + cyclophosphamide, adriamycin, 5FU Recurrence cisplatin/etoposide then carboplatin/etoposide	AC	+	+	NA	3/11	DOD	27
Rose <i>et al</i> ^[18]	Surgery + RT + tamoxifen	DC	+	-	NA	1/15	Unk	Unk
Di Bonito <i>et al</i> ^[19]	Surgery	Unk			NA	11/13	NED	4
Bailey <i>et al</i> ^[20]	Surgery + tamoxifen	DC	+	+	NA	2/20	NED	12
Levin <i>et al</i> ^[21]	Surgery + tamoxifen Recurrence restarted tamoxifen/RT	AC	+	-	+	4/11	NED	24
Kennedy <i>et al</i> ^[7]	Surgery + adriamycin/cyclophosphamide	Unk	-	-	NA	9/9	NED	15
Irvin <i>et al</i> ^[4]	Surgery + cytoxan/Mtx/5FU + RT + tamoxifen	AC	+	+	NA	1/14	NED	4
Gorisek <i>et al</i> ^[22]	Surgery + tamoxifen	AC	+	+	NA	NA	NED	19
Piura <i>et al</i> ^[23]	Surgery + adriamycin/cyclophosphamide/paclitaxel + RT + tamoxifen	AC	+	+	NA	7/15	NED	14
Chung-Park <i>et al</i> ^[24]	Surgery	MU	+	+	-	NA	NED	36
Yin <i>et al</i> ^[25]	Surgery	MU	+	+	-	1/11	NED	9
Lopes <i>et al</i> ^[26]	Surgery + docetaxel/doxorubicin/cyclophosphamide + tamoxifen	MU	+	NA	-	2/13	Unk	Unk
Fracchioli <i>et al</i> ^[27]	Surgery + 5FU/adriamycin/cyclophosphamide + tamoxifen Recurrence-paclitaxel	AC	-	NA	NA	7/7	Rec	36
North <i>et al</i> ^[28]	Surgery + cyclophosphamide/epirubicin/5FU + weekly docetaxel + tamoxifen	DC	+	+	-	5/7	Unk	Unk
Naseer <i>et al</i> ^[29]	Surgery + 5FU/epirubicin/cyclophosphamide + weekly docetaxel + RT + aromatase	DC	+	+	-	3/13	Unk	Unk
McMaster <i>et al</i> ^[30]	Surgery + RT	DC	+	NA	NA	NA	Unk	Unk
Bogani <i>et al</i> ^[13]	Surgery + epirubicin/cyclophosphamide + tamoxifen	DC	+	+	NA	1/8	NED	24

AC: Adenocarcinoma; DC: Ductal carcinoma; DOD: Dead of disease; LO: Lobular; MU: Mucinous; Mtx: Methotrexate; NA: Not applicable; NED: No evidence of disease; Rec: Recurrence; RT: Radiation therapy; S: Squamous; Unk: Unknown; 5FU: 5-fluorouracil.

high and can be difficult to locate; primary surgical excision (radical vulvectomy) with sentinel lymph node dissection to help identify the sentinel lymph node should be considered.

Systemic chemotherapy based on adjuvant therapy platforms for breast cancer with docetaxel or paclitaxel, plus doxorubicin, and cyclophosphamide should be considered. Given the biologic parallels between primary breast and vulvar breast cancer, treatment paradigms mimicking primary breast cancer are a rational approach and are advisable. This is supported by the median survival of patients treated with adjuvant therapy for breast cancer had a mean survival of 30 mo in comparison to 12 mo for those receiving a vulvar treatment (surgery followed by radiation). Finally, patients with estrogen and progesterone receptor positive specimens may be maintained on tamoxifen or aromatase inhibitors.

COMMENTS

Case characteristics

A 62 years old Hispanic women presented with a 1.3 cm left labial mass.

Clinical diagnosis

Suspected neoplasm originating from the left labia.

Differential diagnosis

Gartners duct cyst, labial myoma, vulvar squamous cell carcinoma, and vulvar

melanoma.

Pathological diagnosis

Histologic examination identified the ectopic breast tissue and carcinoma present in excised specimen.

Treatment

Excisional procedure.

Related reports

Previous reports of vulvar breast cancer present similarly with an isolated labial mass, treated with surgical excision, however many do not receive chemotherapy that parallels breast cancer treatments.

Experiences and lessons

When vulvar breast cancer is encountered, the physician should exclude a primary breast malignancy, perform an excision procedure, and utilize sentinel lymph node mapping as recommended in breast cancer.

Peer-review

Well written case report.

REFERENCES

- 1 Nihon-Yanagi Y, Ueda T, Kameda N, Okazumi S. A case of ectopic breast cancer with a literature review. *Surg Oncol* 2011; **20**: 35-42 [PMID: 19853438 DOI: 10.1016/j.suronc.2009.09.005]
- 2 Greene HJ. Adenocarcinoma of supernumerary breasts of the labia majora in a case of epidermoid carcinoma of the vulva. *Am J Obstet Gynecol* 1936; **31**: 660-663
- 3 Visconti G, Eltahir Y, Van Ginkel RJ, Bart J, Werker PM. Approach and management of primary ectopic breast carcinoma in the axilla: where are we? A comprehensive historical literature review. *J Plast Reconstr Aesthet Surg* 2011; **64**: e1-11 [PMID: 20934398 DOI: 10.1016/j.bjps.2010.08.015]

- 4 **Irvin WP**, Cathro HP, Grosh WW, Rice LW, Andersen WA. Primary breast carcinoma of the vulva: a case report and literature review. *Gynecol Oncol* 1999; **73**: 155-159 [PMID: 10094898 DOI: 10.1006/gyno.1998.5269]
- 5 **Marshall MB**, Moynihan JJ, Frost A, Evans SR. Ectopic breast cancer: case report and literature review. *Surg Oncol* 1994; **3**: 295-304 [PMID: 7889223 DOI: 10.1016/0960-7404(94)90032-9]
- 6 **Guerry RL**, Pratt-Thomas HR. Carcinoma of supernumerary breast of vulva with bilateral mammary cancer. *Cancer* 1976; **38**: 2570-2574 [PMID: 187318 DOI: 10.1002/1097-0142(197612)]
- 7 **Kennedy DA**, Hermina MS, Xanos ET, Schink JC, Hafez GR. Infiltrating ductal carcinoma of the vulva. *Pathol Res Pract* 1997; **193**: 723-726 [PMID: 9505265 DOI: 10.1016/S0344-0338(97)80033-7]
- 8 **Giuliano AE**, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Ann Surg* 1994; **220**: 391-398; discussion 398-401 [PMID: 8092905 DOI: 10.1097/00000658-199409000-00015]
- 9 **Edge SB**, Niland JC, Bookman MA, Theriault RL, Ottesen R, Lepisto E, Weeks JC. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. *J Natl Cancer Inst* 2003; **95**: 1514-1521 [PMID: 14559873 DOI: 10.1093/jnci/djg076]
- 10 **Lyman GH**, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB, Bosserman LD, Burstein HJ, Cody H, Hayman J, Perkins CL, Podoloff DA, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2014; **32**: 1365-1383 [PMID: 24663048 DOI: 10.1200/JCO.2005.08.001]
- 11 **Van der Zee AG**, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol* 2008; **26**: 884-889 [PMID: 18281661 DOI: 10.1200/JCO.2007.14.0566]
- 12 **Levenback C**, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. *Gynecol Oncol* 2001; **83**: 276-281 [PMID: 11606084 DOI: 10.1006/gyno.2001.6374]
- 13 **Bogani G**, Uccella S, Cromi A, Casarin J, Donadello N, Ghezzi F. Primary mammary-like ductal carcinoma of the vulva: a case report and analysis of the literature. *Am J Dermatopathol* 2013; **35**: 685-687 [PMID: 23518640 DOI: 10.1097/DAD.0b013e31828484c0]
- 14 **Hendrix RC**, Behrman SJ. Adenocarcinoma arising in a supernumerary mammary gland in the vulva. *Obstet Gynecol* 1956; **8**: 238-241 [PMID: 13349053]
- 15 **Guercio E**, Cesone P, Saracino A, Gatti M, Arisio R, Oberto F. [Adenocarcinoma occurring in an aberrant mammary gland located in the vulva]. *Minerva Ginecol* 1984; **36**: 315-319 [PMID: 6472725]
- 16 **Cho D**, Buscema J, Rosenshein NB, Woodruff JD. Primary breast cancer of the vulva. *Obstet Gynecol* 1985; **66**: 79S-81S [PMID: 4022521]
- 17 **Simon KE**, Dutcher JP, Runowicz CD, Wiernik PH. Adenocarcinoma arising in vulvar breast tissue. *Cancer* 1988; **62**: 2234-2238 [PMID: 3052783 DOI: 10.1002/1097-0142(198811)56:2:10<2234::AID-CNCR2820621027>3.0.CO;2-F]
- 18 **Rose PG**, Roman LD, Reale FR, Tak WK, Hunter RE. Primary adenocarcinoma of the breast arising in the vulva. *Obstet Gynecol* 1990; **76**: 537-539 [PMID: 2199874]
- 19 **Di Bonito L**, Patriarca S, Falconieri G. Aggressive "breast-like" adenocarcinoma of vulva. *Pathol Res Pract* 1992; **188**: 211-214; discussion 214-216 [PMID: 1594493 DOI: 10.1016/S0344-0338(11)81181-7]
- 20 **Bailey CL**, Sankey HZ, Donovan JT, Beith KA, Otis CN, Powell JL. Primary breast cancer of the vulva. *Gynecol Oncol* 1993; **50**: 379-383 [PMID: 8406206 DOI: 10.1006/gyno.1993.1230]
- 21 **Levin M**, Pakarakas RM, Chang HA, Maiman M, Goldberg SL. Primary breast carcinoma of the vulva: a case report and review of the literature. *Gynecol Oncol* 1995; **56**: 448-451 [PMID: 7705684 DOI: 10.1006/gyno.1995.1080]
- 22 **Gorisek B**, Zegura B, Kavalari R, But I, Krajnc I. Primary breast cancer of the vulva: a case report and review of the literature. *Wien Klin Wochenschr* 2000; **112**: 855-858 [PMID: 11098538]
- 23 **Piura B**, Gemer O, Rabinovich A, Yanai-Inbar I. Primary breast carcinoma of the vulva: case report and review of literature. *Eur J Gynaecol Oncol* 2002; **23**: 21-24 [PMID: 11876386]
- 24 **Chung-Park M**, Zheng Liu C, Giampoli EJ, Emery JD, Shalodi A. Mucinous adenocarcinoma of ectopic breast tissue of the vulva. *Arch Pathol Lab Med* 2002; **126**: 1216-1218 [PMID: 12296762 DOI: 10.1043/00039985(2002)126<1216:MAOEBT>2.0.CO;2]
- 25 **Yin C**, Chapman J, Tawfik O. Invasive mucinous (colloid) adenocarcinoma of ectopic breast tissue in the vulva: a case report. *Breast J* 2003; **9**: 113-115 [PMID: 12603384 DOI: 10.1046/j.1524-4741.2003.09213.x]
- 26 **Lopes G**, DeCesare T, Ghurani G, Vincek V, Jorda M, Glück S, Silva O. Primary ectopic breast cancer presenting as a vulvar mass. *Clin Breast Cancer* 2006; **7**: 278-279 [PMID: 16942646 DOI: 10.3816/CBC.2006.n.041]
- 27 **Fracchioli S**, Puopolo M, De La Longrais IA, Scozzafava M, Bogliatto F, Arisio R, Micheletti L, Katsaros D. Primary "breast-like" cancer of the vulva: a case report and critical review of the literature. *Int J Gynecol Cancer* 2006; **16** Suppl 1: 423-428 [PMID: 16515638 DOI: 10.1111/j.1525-1438.2006.00364.x]
- 28 **North J**, Perez D, Fentiman G, Sykes P, Dempster A, Pearce M. Primary breast cancer of the vulva: case report and literature review. *Aust N Z J Obstet Gynaecol* 2007; **47**: 77-79 [PMID: 17261107 DOI: 10.1111/j.1479-828X.2006.00685.x]
- 29 **Naseer MA**, Mohammed SS, George SM, Das Majumdar SK. Primary ectopic breast cancer mimicking as vulval malignancy. *J Obstet Gynaecol* 2011; **31**: 553-554 [PMID: 21823871 DOI: 10.3109/01443615.2011.587054]
- 30 **McMaster J**, Dua A, Dowdy SC. Primary breast adenocarcinoma in ectopic breast tissue in the vulva. *Case Rep Obstet Gynecol* 2013; **2013**: 721696 [PMID: 24066246 DOI: 10.1155/2013/721696]

P- Reviewer: AliR A, Park Y, Peng Y **S- Editor:** Ji FF **L- Editor:** A
E- Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

